-
There is a large space for domestic substitution of pharmaceutical equipment, and pharmaceutical companies have rushed to the market!
Time of Update: 2022-12-30
Chuangzhi Technology plans to invest 550 million yuan this time, and the funds raised will be used for high-end pharmaceutical equipment industrialization construction projects, R&D center construction projects, and supplementary working capital.
-
The pharmaceutical sector has changed! Guizhou Bailing rose to the limit, Xinhua Pharmaceutical, Yiling Pharmaceutical and so on went higher
Time of Update: 2022-12-29
Recently, traditional Chinese medicine stocks have risen again, and the industry believes that in addition to the growth of related drugs brought about by the "20 articles" and autumn and winter, it is mainly closely related to a series of favorable policy support behind it.
-
Today, many pharmaceutical commercial stocks such as Nanjing Pharmaceutical and Jiashitang rose to the limit
Time of Update: 2022-12-29
【Pharmaceutical Network Pharmaceutical Stock Market】 On December 5, the pharmaceutical business sector strengthened, Nanjing Pharmaceutical, Jiashitang rose to the limit, Luyan Pharmaceutical, Inter Group, Sinopharm Consistency, Saili Medical, Kaikai Industry, and BAHEAL Pharmaceutical rose to the limit.
-
Ursodeoxycholic acid concept stocks strengthen! Sinotherapeutical's "one" word is up and down, and many stocks such as Common Pharmaceutical have soared
Time of Update: 2022-12-29
According to the data, Gong Gong Pharmaceutical is an enterprise specializing in the research and development, production and sales of steroid hormone drug raw materials, and its main products are starting materials and intermediates required for the production of steroid drugs 。 According to the 2022 third quarter report of Mutual Pharmaceutical, the company's main revenue in the first three quarters of this year was 447 million yuan, an increase of 0.
-
The dry eye drug market war is about to start! There are already a number of pharmaceutical companies on the track
Time of Update: 2022-12-29
It is reported that Aldeyra recently announced that the company has submitted a new drug application for reproxalap eye drops for the treatment of dry eye syndrome to the US FDA.
-
The localization strategy of domestic pharmaceutical enterprises has been upgraded, and the transformation to innovation has become a trend
Time of Update: 2022-12-29
Carestream Health is trying to broaden its product pipeline, and in the future, the company will continue to tailor products for all levels of the domestic market, and provide broader solutions, so as to achieve full coverage of high-end, high-end and low-end products in the Chinese market, so that innovation can benefit more people.
-
Since the fourth quarter, the pharmaceutical sector has rebounded and risen, and 3 Chinese medicine stocks have risen by more than 100%
Time of Update: 2022-12-29
In addition, Teyi Pharmaceutical said on the interactive platform on December 8 that at present, the company's tablet production capacity is 448,580,000 tablets, and the company will reasonably formulate a production plan for ibuprofen tablets according to market demand.
-
The development power of the domestic pharmaceutical machine industry lies in innovation, so that innovation "landing" into the focus of enterprises
Time of Update: 2022-12-29
It is reported that at present, many pharmaceutical equipment with R&D strength and capital in China are increasing investment in innovation and R&D to accelerate the development of product performance and capacity expansion.
-
The pharmaceutical sector continued to rise sharply, with Sinotheopea, Shuangcheng Pharmaceutical, and Changjiang Health rising to the limit
Time of Update: 2022-12-29
The main business of Shuangcheng Pharmaceutical is the research and development, production and sales of chemically synthesized peptide drugs.
The main business of Shuangcheng Pharmaceutical is the research and development, production and sales of chemically synthesized peptide drugs.
-
The biopharmaceutical equipment industry is showing a high prosperity and will usher in a new outlet for local substitution
Time of Update: 2022-12-29
Industry analysts believe that in the future, under the background of achieving import substitution of biopharmaceutical equipment and accelerating the development of high-end markets, domestic pharmaceutical machine giants with relatively rich experience, large R&D investment and earlier layout are expected to usher in more benefits.
-
Many pharmaceutical stocks closed up and down, and one stock recorded 4 days and 3 boards!
Time of Update: 2022-12-29
On the news, Qianhong Pharmaceutical disclosed a stock trading change announcement on the evening of December 8, saying that the indications of the company's current product ursodeoxycholic acid tablets are cholesterol-type gallstones, formation and bile deficiency steatorrhea, prevention of drug-induced stone formation and treatment of steatorrhea.
-
ICBC Credit Suisse Fund surveyed 5 individual stocks, involving 2 pharmaceutical companies
Time of Update: 2022-12-29
【Pharmaceutical Network Pharmaceutical Stock Market】 According to the public market information and the institutional research information disclosed on December 2, ICBC Credit Suisse Fund recently con
-
The 5 pharmaceutical stocks have been surveyed by more than 20 institutions, involving medical devices, traditional Chinese medicine and other fields
Time of Update: 2022-12-29
According to the author's incomplete statistics, since December this year, the pharmaceutical and biological industry has still received institutional attention, up to now 18 pharmaceutical companies have been investigated by institutions, of which 6 pharmaceutical stocks have been surveyed by more than 20 institutions, including Robust Medical, Jiangzhong Pharmaceutical, Warner Pharmaceutical, Hokuriku Pharmaceutical, Aipeng Medical, etc.
-
In December, 5 innovative drugs may be approved for marketing!
Time of Update: 2022-12-29
In November, the FDA approved a total of 5 new drugs, including Tzield, the world's first innovative anti-diabetes delaying therapy, Hemgenix, the first hemophilia B gene therapy, Sezaby (phenobarbita
-
A pharmaceutical IPO is a leading enterprise in the tide of domestic substitution of high-end equipment
Time of Update: 2022-12-29
0 superconducting magnets to build preclinical MRI systems, which are applied to the development process of innovative drugs, breaking the monopoly of foreign companies in the field of magnetic resonance scientific instruments 。 According to the prospectus, Chenguang Medical's main products have market competitiveness, such as the uniformity of 1.
-
Under the "heat" of domestic AI pharmaceutical, opportunities and challenges coexist!
Time of Update: 2022-12-29
For example, on November 12, Insilico announced that it had reached a drug research and development cooperation with the multinational pharmaceutical company Sanofi.
For example, on November 12, Insilico announced that it had reached a drug research and development cooperation with the multinational pharmaceutical company Sanofi.
-
The biomedical sector bottomed out, and the agency suggested further increasing allocation
Time of Update: 2022-12-29
In January, the "14th Five-Year Plan" for the development of the pharmaceutical industry was released, the main content of which is to strengthen the research of key core technologies and vigorously promote the research and development of innovative products.
-
The concept of ursodeoxycholic acid continued to skyrocket, and Xintai Pharmaceutical, Xinhua Pharmaceutical, etc. rose to the limit
Time of Update: 2022-12-29
The company's main business is the research and development, production and sales of lyophilized powder, lyophilized powder injection (including anti-tumor drugs), small volume injection (non-final sterilization), tablets, hard capsules, granules and APIs within the scope of drug production license.
-
Pharmaceutical stocks once again set off a wave of ups and downs, and also obtained the main funds to continue to increase holdings
Time of Update: 2022-12-29
Today, in addition to the outbreak of pharmaceutical stocks, many stocks rose to the limit; In fact, pharmaceutical stocks have also received the main funds to continue to increase their holdings, with a net purchase of more than 2 billion yuan.
-
Today's innovative drug sector rose strongly, with East China Pharmaceutical and Kanglong Chemical rising considerably
Time of Update: 2022-12-29
Huadong Pharmaceutical and Kanglong Chemical led the rise, and Changchun High-tech, Tigermed Pharmaceutical, and WuXi AppTec led the rise, driving the volume and price of innovative drug ETFs to rise, with the current turnover exceeding 80 million yuan, and the net inflow of funds in the past 5 days was 164 million yuan.
